Clinical Trial Update: An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and effectiveness of nivolumab plus ipilimumab, followed by nivolumab alone, in melanoma with brain metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2021-10-05